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Objectives: It has been suggested that statins have an
effect on the modulation of the cytokine cascade and on
the outcome of patients with community-acquired
pneumonia (CAP). The aim of this prospective,
randomised, double-blind, placebo-controlled trial was to
determine whether statin therapy given to hospitalised
patients with CAP improves clinical outcomes and
reduces the concentration of inflammatory cytokines.
Setting: A tertiary teaching hospital in Barcelona, Spain.
Participants: Thirty-four patients were randomly
assigned and included in an intention-to-treat analysis
(19 to the simvastatin group and 15 to the placebo
group).
Intervention: Patients were randomly assigned to
receive 20 mg of simvastatin or placebo administered in
the first 24 h of hospital admission and once daily
thereafter for 4 days.
Outcome: Primary end point was the time from hospital
admission to clinical stability. The secondary end points
were serum concentrations of inflammatory cytokines
and partial pressure of arterial oxygen/fractional inspired
oxygen (PaO2/FiO2) at 48 h after treatment administration.
Results: The trial was stopped because enrolment was
much slower than originally anticipated. The baseline
characteristics of the patients and cytokine concentrations
at the time of enrolment were similar in the two groups.
No significant differences in the time from hospital
admission to clinical stability were found between study
groups (median 3 days, IQR 2–5 vs 3 days, IQR 2–5;
p=0.47). No significant differences in PaO2/FiO2 (p=0.37),
C reactive protein (p=0.23), tumour necrosis factor-α
(p=0.58), interleukin 6 (IL-6; p=0.64), and IL-10
(p=0.61) levels at 48 h of hospitalisation were found
between simvastatin and placebo groups. Similarly,
transaminase and total creatine kinase levels were similar
between study groups at 48 h of hospitalisation (p=0.19,
0.08 and 0.53, respectively).
Conclusions: Our results suggest that the use of
simvastatin, 20 mg once daily for 4 days, since hospital
admission did not reduce the time to clinical stability and
the levels of inflammatory cytokines in hospitalised
patients with CAP.
Trial registration number: ISRCTN91327214.
INTRODUCTION
Community-acquired pneumonia (CAP) is
one of the most important public health pro-
blems worldwide.1 Although mortality in
patients with CAP fell dramatically with the
introduction of antibiotics in the 1950s, it
has changed very little over the past 50 years.
Recent studies have found overall mortality
rates of 8–15%,2 3 and mortality in patients
with CAP requiring intensive care unit (ICU)
admission can be as high as 30% despite
prompt and appropriate antibiotic therapy.4
The concept of clinical stability is a key com-
ponent of CAPmanagement. It allows decision-
making concerning hospital discharge and
treatment length. Physicians are well aware that
the evolution of hospitalised patients with CAP
within the first days is crucial. In fact, once sta-
bility was achieved, clinical deterioration
occurred in 1% of cases or fewer.5 6 Studies
have shown that excessive inflammatory
response is a major cause of treatment failure
and mortality in patients with CAP.7 8
Therefore, there is a growing interest in identi-
fying drugs that can modulate the inflamma-
tory response in these patients. Recently, it has
been demonstrated that hydroxymethylglutaryl
Strengths and limitations of this study
▪ The treatment was assigned on a random basis.
▪ Another unique feature of this trial was that it
addressed the question of de novo statin use only
in hospitalised patients with community-acquired
pneumonia.
▪ The trial did not achieve its recruitment target for
determining the effects of statins on time to
reach clinical stability.
▪ The exclusion criteria, such as patients receiving
certain drugs that are metabolised by the CYP3A4
enzyme system, are limitations to the external val-
idity of the results.
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(HMG)-coenzyme A reductase inhibitors, commonly
known as statins, have immunomodulatory, antioxidative
and anticoagulant effects. Experimental studies have
shown their effect on the modulation of the cytokine
cascade and on the organisation of the immunological
response to respiratory infection.9 In addition, most obser-
vational studies published to date support the idea that the
use of statins may improve the prognosis of CAP.10–12
However, randomised trials are lacking.
In this study, we hypothesised that statin therapy given
to hospitalised patients with CAP would reduce the time
to clinical stability and the concentration of inflamma-
tory cytokines. The primary end point of this trial was
the time from hospital admission to clinical stability, as
defined elsewhere.5
MATERIALS AND METHODS
Study design and setting
This prospective, randomised, double-blind, placebo-
controlled trial was conducted at Hospital Universitari de
Bellvitge—IDIBELL, a 700-bed public hospital in
Barcelona, Spain, between December 2009 and June 2011.
It was registered at International Standard Randomised
Control Trial Registry (ISRCTN91327214) before initi-
ation. Informed consent was obtained from all patients.
The trial was conducted in accordance with the
Declaration of Helsinki and was reported in agreement
with the key methodological items of the CONSORT
(Consolidated Standards of Reporting Trials) statement.
Patient eligibility and recruitment process
All patients included in the study were at least 18 years of
age, had received a diagnosis of CAP in the emergency
department and had required hospital admission accord-
ing to the following criteria: patients classified in groups
I–III of the Pneumonia Severity Index (PSI)13 with abso-
lute criteria for hospitalisation (need for oxygen therapy
or haemodynamic support, pulmonary cavitation, septic
metastasis, lack of response to outpatient antibiotic
therapy, uncontrollable vomiting). All patients in groups
IV and V of the PSI were also included.
Patients who did not provide prior written consent, who
had immunosuppression (HIV/AIDS, solid organ trans-
plant, stem cell transplantation, antineoplastic chemother-
apy in the previous 30 days, neutropaenia, prior use of
corticosteroids or other immunosuppressants) and preg-
nant women were excluded. Similarly, patients receiving
statins, antidepressants, calcium channel blockers, amio-
darone, azoles, macrolides, niacin, fibric acid and deriva-
tives, protease inhibitors and grapefruit juice were not
eligible. Finally, patients who received antibiotic therapy or
had been admitted more than 24 h prior to enrolment
were also excluded.
Definitions and follow-up
CAP was defined as the presence of an infiltrate on
chest radiography plus at least two of the following: fever
(temperature ≥38°C) or hypothermia (temperature
≤35°C), new cough with or without sputum production,
pleuritic chest pain, dyspnoea, or altered breath sounds
on auscultation. The chest radiograph was interpreted
by the infectious disease consultant.
Clinical and laboratory data (demographic character-
istics, comorbidities, causative organisms, antibiotic suscep-
tibilities, biochemical analysis, empirical antibiotic therapy
and outcomes) on all patients were collected using a
computer-assisted protocol. Patients were seen daily
during their hospital stay by one or more of the investiga-
tors. Pathogens in blood, normally sterile fluids, sputum
and other samples were investigated using standard micro-
biological procedures. Urine antigen tests were performed
for the detection of Legionella pneumophila serogroup
1 (Binax-Now; Binax, Portland, Maine, USA) and
Streptococcus pneumoniae (Binax-Now; Binax, Portland,
Maine, USA). In addition, real-time PCR was used for the
detection of influenza A and B.
Antibiotic therapy was initiated in the emergency
department in accordance with hospital guidelines.
Interventions and randomisation
Patients were randomly assigned to receive 20 mg of sim-
vastatin or placebo, which were administered orally in
the first 24 h of hospital admission and once daily there-
after for 4 days. A 4-day duration of simvastatin therapy
was chosen because of plasma mevalonic acid, the sub-
stance being related to pleiotropic effects, drop up to
70% within 1–2 h after the first administration of statins,
and because of previous studies having administered
immunomodulatory therapies between 3 and 7 days and
the median time to clinical stability in our patients is
nearly 4 days. Trial packs of identical capsules were pre-
pared by the hospital pharmacy and contained either
simvastatin or matched placebo.
Randomisation was performed by using a computer-
generated random code with a block size of 10. The
random code was held centrally by the clinical epidemiolo-
gist and was delivered directly to the pharmacist in charge
of the preparation of the masked capsules. All clinical and
study personnel, and patients, remained blinded to the
study group assignment throughout the trial.
End points
Primary end point of the trial was the time (days) from
hospital admission to clinical stability, as described
elsewhere.5 Clinical stability was measured daily during
hospitalisation. Secondary end points were serum concen-
trations of inflammatory cytokines (C reactive protein,
tumour necrosis factor-α (TNF-α), interleukin 6 (IL-6)
and IL-10) and partial pressure of arterial oxygen/frac-
tional inspired oxygen (PaO2/FiO2) at 48 h after treat-
ment administration. Similarly, aminotransferases and
total creatine kinase were determined at 48 h after admis-
sion to evaluate the potential toxicity of treatment.
To determine the cytokine concentrations, 10 mL of
venous blood was obtained within 24 h of hospital
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admission and after 48 h. Samples were centrifuged at
4000 rpm for 15 min at room temperature. The serum
was separated, divided into aliquots and frozen at −80°C
within 6 h of extraction. For analysis, serum was thawed
and TNF-α, IL-6 and IL-10 serum concentrations quanti-
fied by Invitrogen Human ELISA kits (Life Technologies)
according to the manufacturer’s instructions.
Statistical analysis
In the original analysis, we calculated the sample size on
the hypothesis that simvastatin could reduce the time to
reach clinical stability by 1.5 days. With a reference time
to reach clinical stability of 5 days, we calculated that 175
patients were needed in each group to detect this differ-
ence with a power of 80% and a type 1 error of 5% (two
sided).
Categorical variables were described using counts and
percentages. Continuous variables were expressed as the
median and IQR. Baseline data between the two study
groups were compared by means of the non-parametric
Mann-Whitney U test for continuous data and by the χ2
test for categorical data. For 2×2 tables in which cells con-
tained fewer than five observations, Fisher’s exact two-
tailed test for categorical data was used. The Wilcoxon
signed-rank test was used to compare two related mea-
surements. In addition, analysis of covariance (ANCOVA)
was performed to compare the cytokines values at 48 h in
the two groups, adjusting for baseline values.
Data for the end point was analysed on intention-to-treat
analysis. A p Value of <0.05 was considered statistically sig-
nificant. All reported p values are two tailed. All statistical
calculations were performed using the SPSS (V.15.01s) for
Windows (SPSS Inc, Chicago, Illinois, USA).
RESULTS
The screening for inclusion criteria was started in
December 2009 and ended in June 2011 due to slow
recruitment because of the exclusion criteria of the study.
Most excluded patients were receiving statins, other
drugs that are metabolised by the CYP3A4 enzyme system
or antibiotic therapy prior to enrolment. Thirty-four
patients were randomly assigned and included in an
intention-to-treat analysis for the end point (19 to the
simvastatin group and 15 to the placebo group). Figure 1
shows the study profile. The baseline characteristics of
the patients at the time of enrolment were similar in the
two groups and are detailed in table 1. No significant dif-
ferences between groups were documented in the clinical
features and severity of patients, the aetiology of CAP, and
the type of empirical antibiotic therapy and the time
since hospital admission to antibiotic administration.
No significant differences in the time from hospital
admission to clinical stability were found between study
groups (median 3 days, IQR 2–5 vs 3 days, IQR 2–5;
p=0.47).
Table 2 compares serum cytokine concentrations and
PaO2/FiO2 in the two groups. No significant differences in
TNF-α, IL-6 and IL-10, C reactive protein and PaO2/FiO2
levels at admission and at 48 h of hospitalisation were
found between simvastatin and placebo. However, there
were significant changes in cytokine levels at admission
compared with those at 48 h during hospitalisation in
each group (figure 2). The median change from baseline
to 48 h of PaO2/FiO2 and cytokines between study groups
did not differ significantly (table 3). A post hoc subgroup
analysis in patients with and without corticosteroids did
not find significant differences among cytokines in the
study groups (data not shown).
Figure 1 Flow chart of the trial.
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Transaminase (alanine transaminase and aspartate
transaminase) and total creatine kinase levels were
similar in the simvastatin and placebo groups at 48 h of
hospitalisation (table 4). One patient (in the simvastatin
group) required ICU admission and one patient died
(in the placebo group).






Age, median (IQR), years 63 (44.5–79) 76 (45.5–78)
Male sex 14 (73.7) 12 (80)
Current smoker 4 (21.1) 4 (26.7)
Comorbidities* 12 (63.2) 9 (60)
Charlson Comorbidity Index 1 (0–1.5) 1 (0–1)
Clinical features
Impaired consciousness 2 (10.5) 2 (13.3)
Hypotension 1 (5.3) 2 (13.3)
Hypoxaemia 12 (63.2) 9 (60)
Multilobar pneumonia 6 (31.6) 5 (33.3)
Leucocytosis (leucocytes >12 109/L) 14 (73.7) 8 (53.3)
IDSA/ATS criteria for ICU admission1 4 (21) 5 (33.3)
CAP-specific scores
High-risk PSI classes 8 (42.1) 8 (53.3)
Aetiology†
All 11 (57.9) 11 (73.3)
Streptococcus pneumoniae 8 (42.1) 8 (53.3)
Haemophilus influenzae 0 (0) 2 (13.3)
Influenza A (H1N1) pdm09 1 (5.3) 1 (6.7)
Time to antibiotic administration, median (IQR), hours 5.5 (3–8) 5 (4–7.5)
Treatment at admission
Corticosteroids 8 (42.1) 4 (26.7)
β-lactams 15 (78.9) 12 (80)
Quinolones 15 (78.9) 9 (60)
Mechanical ventilation 1 (5.3) 0 (0)
Data are reported as n (%), unless otherwise indicated.
*Comorbidities included chronic pulmonary diseases, chronic heart diseases, diabetes mellitus, chronic liver disease, chronic kidney disease,
dementia and cerebrovascular disease.
†Other aetiologies in the simvastatin group were Mycoplasma pneumoniae and Chlamydia pneumoniae (one case of each).
ATS, American Thoracic Society; CAP, community-acquired pneumonia; ICU, intensive care unit; IDSA, Infectious Diseases Society of
America; PSI, pneumonia severity index.






Within 24 h of admission
PaO2/FiO2 276.1 (261–299) 276.3 (243–320) 0.90
TNF-α (pg/mL) 24 (22.3–61.7) 30.6 (20.5–38) 0.96
IL-6 (pg/mL) 700 (171–1908) 362 (239–515) 0.91
IL-10 (pg/mL) 8.35 (1.5–38.8) 3.2 (2.4–8.3) 0.17
At 48 h during hospitalisation
PaO2/FiO2* 300 (285–374) 338.1 (314–401) 0.37
CRP (mg/dL) 151.2 (59.5–243.6) 69.4 (27.5–212.2) 0.23
TNF-α (pg/mL)* 19.9 (16.7–40.8) 20.6 (15.8–25.5) 0.58
IL-6 (pg/mL)* 141 (8–192) 66 (37.5–97) 0.64
IL-10 (pg/mL)* 1.31 (0.4–3.8) 1.16 (0.45–2.2) 0.61
CRP levels at baseline were not available.
*p Values for ANCOVA analysis for PaO2/FiO2, TNF-α, IL-6 and IL-10 were 0.33, 0.97, 0.31 and 0.55, respectively. Data are reported as
median (IQR).
ANCOVA, analysis of covariance; CRP, C reactive protein; FiO2, fractional inspired oxygen; IL, interleukin; PaO2, partial pressure of arterial
oxygen; TNF, tumour necrosis factor.
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DISCUSSION
This is a prospective, randomised, double-blind, placebo-
controlled trial that evaluated the use of statins in
patients with CAP. We were unable to find that the use
of 20 mg of simvastatin, once daily for 4 days in addition
to the usual care, reduces the time from hospital admis-
sion to clinical stability and the concentrations of inflam-
matory cytokines in hospitalised patients with CAP.
No prior randomised study has evaluated the effect of
statins on inflammatory cytokine levels or clinically rele-
vant outcome parameters in hospitalised patients with
CAP. Observational studies including prior users of the
drug have related statin therapy with better outcomes in
patients with CAP.10–12 However, an observational study14
suggested that the healthy user bias has a significant role
as a confounding factor in the results. Certainly, the
limitations of studies of this kind do not allow the appli-
cation of their findings in clinical practice.
In a recent study involving adult intensive care patients
with different infections and severe sepsis (mainly lung,
urinary and intra-abdominal infections), the investigators
did not find differences in IL-6 concentrations between
atorvastatin (20 mg daily) and placebo groups.15
Importantly, another study did not support a beneficial
effect of continuing pre-existing statin therapy (atorvastatin
20 mg daily) on sepsis and inflammatory parameters in
patients with presumed infection16; no significant differ-
ences in IL-6 and C reactive protein decreases were docu-
mented at any follow-up time-point in either study group.
However, a randomised study in patients with acute bacter-
ial infections found that statin therapy (40 mg of simvasta-
tin, followed by 20 mg of simvastatin) was associated with a
Figure 2 Changes in the cytokine concentrations at admission compared with those at 48 h during hospitalisation in each study
group. Concentrations are shown in a logarithmic scale (y axis). All cases, Wilcoxon signed-rank test p<0.001 (IL, interleukin;
TNF, tumour necrosis factor).





PaO2/FiO2 −25.4 (0 to −68.6) −64.7 (15.5 to −173.3) 0.37
TNF-α (pg/mL) 5.1 (3.9–14.4) 10.2 (3.2–13.9) 0.64
IL-6 (pg/mL) 463 (45.5–1579.5) 354 (169.5–413.5) 0.87
IL-10 (pg/mL) 4.1 (1.1–12.5) 1.8 (0.6–2.9) 0.14
Data are reported as median (IQR).
FiO2, fractional inspired oxygen; IL, interleukin; PaO2, partial pressure of arterial oxygen; TNF, tumour necrosis factor.
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reduction in the levels of inflammatory cytokines.17 A post
hoc analysis of the subgroup of 48 patients with pneumonia
revealed a significant decrease in IL-6 levels, but not in
TNF-α levels. Nevertheless, it should be noted that IL-6
levels increased at 72 h in the placebo group. Moreover, a
randomised trial found that the acute administration of
40 mg of atorvastatin daily in patients with sepsis may
prevent sepsis progression.18 The authors postulated that
statins may modulate the pathophysiology of sepsis, thereby
restoring endothelial integrity and thus blocking one of
the mechanisms in the development of multiorgan failure.
Notably, inflammatory cytokines were not evaluated.
Finally, a recent study documented that rosuvastatin did
not improve clinical outcomes in patients with sepsis-
associated acute respiratory distress syndrome.19
Our study suggests that simvastatin does not exert an
effect on inflammatory cytokine levels in hospitalised
patients with CAP. We evaluated the change in cytokine
concentrations within the patient, and between simvasta-
tin and placebo groups. The cytokine concentrations
decreased rapidly during the first days of hospital admis-
sion in both study groups, and no significant differences
were documented at 48 h in cytokine levels between sim-
vastatin and placebo groups. However, cytokine levels
were quantified only at baseline and at 48 h, which limits
the assessment of statin effects on the further course of
the inflammatory response. In addition, it is possible that
higher doses of simvastatin17 or the use of other statins18
could have produced different results. A 20 mg dosage
was selected to address concerns regarding potential tox-
icity. Interestingly, in a caecal ligation and perforation
model of sepsis in mice, Merx et al20 documented that
anti-inflammatory properties vary between individual
statins.
Among the strengths of this study is the fact that the
treatment was assigned on a random basis. Another
unique feature of this trial was that it addressed the ques-
tion of de novo statin use only in hospitalised patients with
CAP. In this regard, a recent study documented major dif-
ferences in the early status of the immune system in rela-
tion to the underlying type of infection and concluded
that therapeutic immunointerventions may be directed
by the nature of infection.21 In addition, importantly, our
study suggest the safety profile of simvastatin in this
context. However, it should be noted that patients receiv-
ing certain drugs that are metabolised by the CYP3A4
enzyme system were excluded. This is because of the
increased risk of rhabdomyolysis during concomitant use
of simvastatin, a CYP3A4 substrate statin and CYP3A4
inhibitors,22 and legal aspects related to the responsibility
insurance of the study.
Moreover, there are certain limitations that should be
acknowledged. First, the trial did not achieve its recruit-
ment target for determining the effects of statins on
time to reach clinical stability. Nevertheless, previous
studies faced similar recruitment problems when con-
ducting sepsis-related searches. Second, only systemic
cytokine measurements were performed in our study,
and this response might differ from that encountered
in the lung. Similarly, biomarkers for evaluating coagu-
lation or cardiovascular dysfunction were not evaluated.
In addition, other potential benefits of statins in CAP
were not assessed in the present study, including stabil-
isation of the cardiovascular system to avoid acute
cardiac events and their potential antiviral and antibac-
terial effects. Third, some baseline characteristics, such
as corticosteroid use and long time to first antibiotic
dose may complicate analysis of cytokine levels.
However, no significant differences were observed
between study groups regarding these topics. Finally,
although our study population is representative of
patients hospitalised with CAP since the clinical features
were similar to those reported in other studies, the
exclusion criteria are important limitations to the exter-
nal validity of the results. In addition, a clinical trial
designed with the exclusion criteria used in the present
study is likely difficult, mainly due to the need to
recruit an adequate number of patients.
In summary, we did not find that adding simvastatin,
at a dose of 20 mg daily for 4 days, to the usual treat-
ment of hospitalised patients with CAP decreases the
time from hospital admission to clinical stability and the
inflammatory cytokine levels. Owing to the difficulty of
recruiting patients without exclusion criteria, multicen-
tre randomised studies are needed to determine the
precise role of statins on clinically relevant outcome
parameters in patients with this infection.
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AST level, median (IQR), (ukat/L) 0.25 (0.22–0.36) 0.7 (0.3–0.94) 0.08
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